© Drug Hunter Inc. 2018-2023
Home > BMS-986144
pan-genotype HCV NS3/4A protease inhibitor
proj. oral QD dosing, well-tolerated in rodent
deuteration reduced CYP TDI
J. Med. Chem., Nov. 23, 2020
Bristol-Myers Squibb, NJ + MA + CT + IN
Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year